Clinical Trial

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07522151
Lead Sponsor Shanghai Shengdi Pharmaceutical Co., Ltd
Conditions Locally Advanced Gastric or Gastroesophageal Junction Cancer
Enrollment 874 participants
Start Date 2026-05-07
Primary Completion 2029-12 (estimated)
Study Completion 2034-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-13